This review aims to assemble many years of research and clinical experience in the fields of neurodevelopment and neuroscience to present an up-to-date understanding of the clinical presentation, molecular and brain pathology associated with Fragile X syndrome, a neurodevelopmental condition that develops with the full mutation of the FMR1 gene, located in the q27.3 loci of the X chromosome, and Fragile X-associated tremor/ataxia syndrome a neurodegenerative disease experienced by aging premutation carriers of the FMR1 gene. It is important to understand that these two syndromes have a very distinct clinical and pathological presentation while sharing the same origin: the mutation of the FMR1 gene; revealing the complexity of expansion genetics. Keywords: Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome, FXTAS, FMR1 gene, neuropathology J o u r n a l P r e -p r o o f Journal Pre-proof J o u r n a l P r e -p r o o f Journal Pre-proof
Introduction
association with ribosomes of the endoplasmic reticulum, and at high levels in dendritic spines (32) . FMRP can also appear in cytoplasmic granules that are transported to dendrites, axons, and pre-synaptic terminals in some neurons (33) (34) (35) (36) (37) (38) , enabling localized translation (39) (40) (41) . FMRP granules are also present in axon growth cones during development, likely playing a role in axon guidance, circuit formation, and synaptogenesis (36, 38, 39) .
FMRP is an RNA binding protein that regulates translation of numerous associated mRNAs.
FMRP is largely considered a translational repressor that suppresses translation initiation and elongation of nascent proteins (reviewed extensively in 42, 43) . FMRP also binds and regulates miRNA and miRNA machinery (43, 44) , thus exerting translational control through a separate but complimentary molecular mechanism. Accordingly, due to a loss of FMRP mediated translational repression, there is a modest (10-20%) but functionally significant elevation in FMRP-regulated proteins in FXS patients and in FMR1 KO mice (43) .
Some key FMRP regulated mRNAs/proteins include second messenger proteins involved in mGluR 1 and mGluR 5 signal transduction (EIF4E and S6K), (34, 35, 45) , GABA A and GABA B receptor subunits (46) (47) (48) , numerous voltage gated ion channels (49) (50) (51) , Bone morphogenic protein receptor 2 (BMPR2) (52) , matrix metalloproteinase 9 (MMP9) (53) , and amyloid precursor protein (APP) (54, 55) . Many of these affected mRNA/protein species play a direct role in synaptic transmission. FXS dendrites in the cortex and hippocampus show increased spine density and size, and reduced spine maturity (36, 56, 57) . FMRP mediated suppression of the FMPR2-Cofilin pathway is necessary for normal dendrite formation and maturationand accordingly disruption in this pathway through a loss of FMRP contributes to dendritic abnormalities in FXS. Suppression of MMP9, which is upregulated in the FMR1 KO mouse, normalizes dendritic spine morphology and synapse formation (58) . Additionally, loss of FMRP J o u r n a l P r e -p r o o f leads to excess soluble APP levels, which also contributes to a lack of dendrite maturation (55) .
Normalizing APP levels in FMR1 KO mice rescues alterations in synaptic spines, LTP deficits, and reduces audiogenic seizures (54) .
The excitation/inhibition imbalance hypothesis has been proposed to explain how cellular and circuit-level alterations in excitatory/inhibitory signaling may lead to clinical symptomology in idiopathic ASD (59) . Given the tremendous overlap in FXS and ASD symptomology, as well as the high rates of co-diagnosis in patients with FXS, this hypothesis is believed to largely apply to FXS as well. One way in which excitation and inhibition balance may be disrupted in FXS is through dysregulation of glutamatergic and GABAergic signal transduction. FMRP binds and regulates second messenger proteins that mediate metabotropic glutamate receptor I family (mGluR 1 and mGluR 5 ) signal transduction. When FMRP is absent, there is increased phosphorylation of two such downstream effectors -eukaryotic translation initiation factor 4E (EIF4E) and ribosomal protein S6 kinase (S6K), which leads to excess translation of mRNAs that are typically bound and regulated by FMRP (45, 60, 61) . There is an increase in synaptic long-term depression (LTD) in FMR1 KO mice, which is believed to be related to dysregulation in mGluR 1 signaling. Another consequence of mGluR 1 signaling dysfunction in FXS is a reduction in inhibitory retrograde endocannabinoid signaling by mGluR 1 + dendrites (7, 62) , which likely leads to increased glutamatergic signaling from upstream pre-synaptic glutamatergic neurons and increased excitatory tone. Deficits in GABA signaling have also been characterized in the FMR1 KO mouse, suggesting that a lack of inhibitory GABAergic tone could also lead to hyperexcitability in the FXS CNS.
Neuropathology

J o u r n a l P r e -p r o o f
Structural MRI studies have identified a pattern of regional volume alterations in patients with FXS, characterized by an enlargement in the caudate nucleus (63) (64) (65) (66) (67) and lateral ventricles (63, 64, 66) , and a reduction in cerebellar vermis (63, 66, 68) . Alterations in caudate and cerebellar vermis appear as early as one year of age (69) , and persist into adulthood (63, 66) . There also appears to be a moderate and region-specific alteration in cortical lobe grey matter volume, with modest reductions in temporal (63, 67) and frontal lobes (63, 65) , and a modest increase in the parietal (63, 65) and occipital lobes (63, 65) . Although less consistent, volumetric reductions of amygdala (63, 70) and enlargement of hippocampus (71) have sometimes been observed. White matter volumetric alterations have also been detected, including increased white matter volume in the septal fornix (67), increased brainstem-hippocampus tract and cingulate-corpus callosum tract volume (65) , and decreases in frontal lobe (65) and cerebellar white matter (67) . Most human FXS structural abnormalities are not recapitulated in the FMR1 KO mouse -striatal volume is unaltered (72) or reduced (73, 74) , and there is no change in cerebellar vermis volume (72) (73) (74) or cortical lobe volume (72, 73) .
The neuropathological correlates of these structural abnormalities in the human FXS brain are poorly characterizedthere only exist a handful of such studies and all typically have very small sample sized (n ≤ 3 for all). The earliest and most well characterized finding demonstrated that there are alterations in dendrites and synaptic spines in the postmortem FXS brain. More specifically, FXS cortical tissue in the occipital and temporal cortices have more dendritic spines (56) , and these spines are longer and immature (57, 75) . Ultrastructural analysis also shows a reduction in synaptic size at dendritic contacts (57) . Cerebellar Purkinje cells are reduced in number (76, 77) and in dendritic arbor complexity (76) , and the hippocampal structure presents with restricted hyperplasia in the CA1 region (76) . Structural and functional MRI studies have J o u r n a l P r e -p r o o f Journal Pre-proof both been able to correlate abnormal activation patterns with specific symptom domains in FXS patients. For example, intellectual functioning, as indicated by IQ, is inversely correlated with caudate volume (65) and positively correlated with cerebellar vermis volume (63) .
Fragile X-associated Tremor/Ataxia Syndrome
Clinical Aspects
First described in a publication in 2001, fragile X-associated tremor/ ataxia syndrome (FXTAS)
is a neurodegenerative disease that primarily affects premutation carriers (55 to 200 CGG repeats) and clinically presents with the core features of intention tremor and/or cerebellar gait ataxia (1) . While different in etiology, FXTAS like FXS is more common in males due to the Xlinked etiology of the FMR1 gene. It is estimated from one study in United States that 1 in every 403 men are FMR1 premutation carriers and of those, 40% will be diagnosed with FXTAS by their seventh decade. In comparison, women premutation carriers have a prevalence of 1 in every 209 and only an estimated 16% chance of developing FXTAS due to their having one regular functioning X chromosome (78, 79) . It is worth noting that while premutation carrier women develop FXTAS at lower rates, they are at risk for fragile X-associated primary ovarian insufficiency (FXPOI), the most heritable form of premature menopause or early ovarian failure.
In addition, female premutation carriers report higher rates of psychiatric symptoms including anxiety, ADHD, depression, insomnia, chronic fatigue, and chronic pain. Which fall under the umbrella term of FXAND (4). While not all premutation carriers go on to develop FXTAS the prevalence for FXTAS does increase in age with one study of premutation men showing 17% being affected at 50 years, 38% at 60 years, 47% at 70 years, and 75% at 80 years of age (80) J o u r n a l P r e -p r o o f
The hallmark radiological sign of FXTAS is an increased signal on a T2 flair MRI sequence in cerebral white matter especially on the middle cerebellar peduncles (MCP) (81) . This characteristic sign is not often seen in women; however, MRI scans of female FXTAS brains reveal increased signal in the splenium of the corpus callosum and in the pons (82) . Moderate to severe cortical and general atrophy and increased ventricular volumes is seen in both genders.
One study that analyzed 322 magnetic resonance imaging scans confirmed that overall brain and cerebellar volumes were statistically smaller in premutation carrier males with FXTAS as compared to premutation carrier males without FXTAS and controls (83) . Another study in young asymptomatic premutation carriers found no differences in measures of executive function with aged matched controls however, the premutation carriers showed a significantly longer manual movement and reaction times. Suggesting that these cerebellar changes might underlie motor deceleration that occurs before symptoms are detected (84) .
Diagnostic Criteria
After the FMR1 mutation is confirmed as a premutation carrier status, diagnosis is often made after patients approach their physician with complaints of an action tremor and/or an increase in falls and unsteadiness or ataxia.
A definite diagnosis of FXTAS is given if the FMR1 premutation carrier presents with at least one major radiological sign (refer to Currently there is no cure for FXTAS and treatment is based on alleviation of symptoms, such as the use of primidone or beta blockers for the tremor and SSRIs for irritability or depression.
Molecular Pathology
In contrast to FMR1 full mutation, which leads to transcriptional silencing of FMR1 mRNA and a concomitant loss of FMRP, in FXTAS there is not a substantial alteration in FMRP levelsonly a modest reduction in the high premutation repeat range ( Fig 1B) . However, in premutation cases there is a dramatic increase in FMR1 mRNA (Fig. 1B) . There are three primary molecular mechanisms by which FMR1 premutation excess mRNA is believed to lead to FXTAS neuropathology (5, 87), including: 1) Sequestration of proteins and RNAs into inclusion bodies R-loop formation leading to DNA damage; and 3) RAN translation leading to the production of toxic FMRpolyG protein (Fig. 1B ). In addition, elevated mRNA levels lead to elevated levels of Ca +2 in the neuron and subsequent mitochondrial dysfunction which worsens as FXTAS develops (88) . These proposed mechanisms are not mutually exclusive, and there may remain other yet unidentified molecular mechanisms by which FMR1 premutation leads to pathogenesis.
The first mechanism proposed for how FMR1 premutation leads to FXTAS is that FMR1 premutation mRNA sequesters other RNA and protein species into intranuclear inclusion bodies, which in turns disrupts essential cellular processes dependent on these molecules. Inclusion bodies are the hallmark neuropathological indicator of FXTAS; they contain FMR1 mRNA but J o u r n a l P r e -p r o o f lack FMRP (87, 89) , and are exclusively located within the nucleus (90) (91) (92) (93) . Inclusions are almost always present as a single body (90, 91, 93, 94) , with the exception of Purkinje cells that sometimes form twin inclusions (95) . FACS sorting in combination with inclusion autofluorescence has enabled improved isolation and purification of inclusion bodies, revealing some of their basic biochemistry (87) . Inclusions are predominantly an aggregate of protein, composed of a heterogenous assortment of many proteins which are particularly enriched in RNA-binding, DNA-binding, and protein turnover regulating proteins (87) . The inclusions also contain mRNA species, but to a much lower degree than protein, and inclusions do not contain DNA (87) . Five proteins are particularly enriched: SUMO2, p62/SQSTM1, Myeloid Leukemia The third proposed molecular mechanism in FXTAS is RAN (non-AUG) translation (reviewed extensively in 103, 104) . RAN translation is a common feature in triplet repeat expansion disorders, whereby regions of an mRNA containing the triplet repeat become prone to errors in translation and protein synthesis is initiated outside of the traditional AUG start codon (105-109) (107, (109) (110) (111) . In FXTAS, the non-coding region of FMR1 premutation mRNA is translated into multiple RAN translation proteins, including the FMRpolyG protein being the most highly expressed and thus likely the largest contributor to pathology (105, 106) . Sellier et al. (105) reported that FMRpolyG protein is present in inclusion bodies that form in the cytosol, and that these FMRpolyG positive inclusions are subsequently transported into the nucleus where they disrupt the nuclear lamina protein LAP2β, leading to toxicity. They also reported that this toxicity only occurs when FMRpolyG proteins are produced from FMR1 premutation mRNA in transgenic rodent models, and that increasing expression of LAP2β ameliorates FMRpolyG toxicity (105) . Numerous studies have identified the presence of intranuclear FMRpolyG+ and FMRpolyA+ inclusions in FXTAS postmortem human brain (105, (112) (113) (114) and peripheral tissue (114, 115) , as well as in FMR1 premutation rodent models (105, 116, 117) . Multiple studies in FXTAS rodent, fly, and cell culture models have also demonstrated that expression of FMR1 RAN translation products are necessary for inclusion formation and toxicity (105, 106, 118, 119) . However while it is clear that RAN translation does occur in humans with FXTAS, whether it is a central driver of pathogenesis remains unclear. In a recent study utilizing mass spectroscopy to analyze human FXTAS inclusion composition, Ma et al (87) indeed detected RAN translation products in human FXTAS brain tissue, but also found using parallel reaction J o u r n a l P r e -p r o o f monitoring that they occurred in very low abundance and were not localized within FXTAS inclusion bodies. Future studies are needed to expand upon and further clarify the relative contribution of these three proposed mechanisms of FMR1 premutation toxicity, in addition to identifying other possible molecular mechanisms that may also co-occur.
Neuropathology
The hallmark pathological change in FXTAS is the presence of intranuclear inclusion bodies ( Fig. 2D /E) that are ubiquitin and FMR1 mRNA positive (90, 91, 120) . FXTAS inclusion burden is positively correlated with CGG repeat length within the premutation range (90) . In the CNS, FXTAS inclusions occur in astrocytes and neurons, although they tend to be larger and occur at a higher frequency in astrocytes in male cases (90, 91, 120) . There is a regional variability in the proportion of neurons and astrocytes bearing inclusions. At one extreme, there tend to be no inclusion+ neurons in the pons, although inclusion+ astroctyes are abundant occurring in 9-30% of cells (90) . Inclusion+ neurons and astrocytes are particularly prevalent in the hippocampus (up to 40% of both cell types) and to a lesser degree in the frontal and temporal cortex (≤10% of neurons and ≤20% of astrocytes) (90, 91, 120) . Neuronal and astrocytic inclusions also occur in the putamen, globus pallidus, substantia nigra, and amygdala (91, 121) . Inclusion bodies are also present in the periphery, including in the peripheral nervous system, enteric nervous system, endocrine glands, heart, and kidney (94, 122) .
Gross pathological assessment of the FXTAS brain indicates severe white matter disease, atrophy of both grey and white matter, and ventricular enlargement ( Fig. 2A) (90, 91, 120) .
Spongiosis and discoloration of cerebellar white matter is present in the vast majority of FXTAS J o u r n a l P r e -p r o o f Journal Pre-proof cases ( Fig. 2B/C) (90, 91, 120) , including the MCP (90) . Cerebral white matter disease is also common, but less consistently than in the cerebellum (90) . Microscopic evaluation of white matter demonstrates a loss of myelin, as well as axonal degeneration (90) . Grey matter atrophy of frontal cortex, cerebellum, and the pons have been qualitatively documented and consistently occur in FXTAS cases (90, 91) . While grey matter neuronal and possibly astrocytic cells loss is presumed, the relative contributions of cellular atrophy and cell loss to regional volumetric reductions have not been directly assessed. Grey matter neuronal loss has so far only been demonstrated to occur in Purkinje cells (90, 91) , and to date has not been systematically assessed in other brain regions or cell types. Female FXTAS cases that present clinically with dementia symptomology also tend to show high rates of comorbid Alzheimer's neuropathology, including significant amyloid plaques and neurofibrillary tangles (120) . Finally, postmortem FXTAS brains show high levels of iron accumulation in brain capillaries and parenchyma ( Fig. 2H/I) , as well as choroid plexus, which can occur as extracellular or intracellular deposits (123) (124) (125) .
Striatal iron accumulation is prevalent and severe (123) , while cerebellar iron accumulation occurs in a smaller subset of patients (<25%) and at lower levels (125) . The iron binding protein ceruloplasmin is also dramatically reduced in neurons and astrocytes, and to a lesser degree in oligodendrocytes (123) , suggesting that FXTAS associated dysregulation of iron metabolic pathways may underlie iron accumulation. In contrast, ceruloplasmin and transferrin expression is increased in microglia, as well as intracellular iron deposits, suggesting that microglia may be actively attempting to counteract iron accumulation (123) . Astrocytes show profound reactive gliosis and profound microglial activation occurs in a majority of FXTAS cases (Fig. 2F /G) (126) . Microglial senescence also occurs in FXTAS suggesting that disease-associated microglial impairment may further exacerbate FXTAS neuropathology (126) .
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Conclusion
Many physicians confuse FXS and FXTAS so it is essential to remember that these are 2 very different disorders, one causing ID and autism and the other leading to neurodegeneration in otherwise normally developed individuals who are aging. Each disorder has differing levels of CGG repeats with deficient levels of FMRP in FXS and elevated levels of FMR1 mRNA in FXTAS. However, these disorders are usually found in the same families and often multiple individuals with each of these disorders can be found. Therefore, when one individual is identified with a fragile X mutation the whole family through multiple generations are at risk for one or more of these mutations. Cascade testing for these mutations are necessary throughout the family tree either by the physician who identified the initial mutation or by referral to genetics so that the whole family can understand and be tested for these disorders. 
